Design and conduct considerations for studies in patients with hepatic impairment-Reference-Cited by-同舟云学术

Design and conduct considerations for studies in patients with hepatic impairment

Author:

Ravenstijn Paulien¹,Chetty Manoranjenni²,Manchandani Pooja³^ORCID,Elmeliegy Mohamed⁴,Qosa Hisham⁵,Younis Islam⁶

Affiliation:

1. Clinical Pharmacology Affimed GmbH Heidelberg Germany

2. Discipline of Pharmaceutical Sciences College of Health Sciences University of KwaZulu Natal Berea South Africa

3. Clinical Pharmacology and Exploratory Development Astellas Pharma US Inc. Northbrook Illinois USA

4. Clinical Pharmacology Global Product Development Pfizer Inc. San Diego California USA

5. Clinical Pharmacology and Pharmacometrics Bristol Myers Squibb Princeton New Jersey USA

6. Clinical Pharmacology Gilead Sciences Foster City California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

Reference53 articles.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献